Skip to main content
. 2022 Feb 10;28(7):1302–1312. doi: 10.1158/1078-0432.CCR-21-3597

Table 1.

Patient demographics and baseline characteristics in patients with NTRK fusion-positive solid tumors.

Characteristic NTRK efficacy-evaluable population (n = 121)
Age, y Median (range) 57.0 (21–88)
Sex, n (%) Female/male 62 (51.2)/59 (48.8)
Race, n (%) White/Asian/Black or African American/other or not reported 73 (60.3)/29 (24.0)/3 (2.5)/16 (13.2)
History of smoking (n = 118), n (%) No/yes 72 (61.0)/46 (39.0)
ECOG PS, n (%) 0/1/2 53 (43.8)/57 (47.1)/11 (9.1)
Prior lines of systemic therapya, n (%) 0/1/2/3/≥4 37 (30.6)/35 (28.9)/26 (21.5)/12 (9.9)/11 (9.1)
Any previous therapyb, n (%) Chemotherapy/targeted therapy/hormonal therapy/immunotherapy 88 (72.7)/24 (19.8)/10 (8.3)/13 (10.7)
CNS metastases at baselinec, n (%) Present/measurable/absent 20 (16.5)/6 (5.0)/95 (78.5)
Prior radiotherapy of the braind (n = 26), n (%) Yes/no 17 (65.4)/9 (34.6)
Time from end of prior radiotherapy of the brain to first dosee, n (%) <2 mo/2 to <6 mo/≥6 mo 7 (41.2)/5 (29.4)/5 (29.4)
NTRK fusion, n (%) NTRK1/NTRK2/NTRK3 48 (39.7)/6 (5.0)/67 (55.4)
Tumor categoryf, n (%) Sarcoma 26 (21.5)
Salivary (MASC) 24 (19.8)
NSCLC 22 (18.2)
Thyroid 13 (10.7)
Colorectal 10 (8.3)
Breast 7 (5.8)
Neuroendocrine 5 (4.1)
Pancreatic 4 (3.3)
Cancer of unknown primary 3 (2.5)
Gynecologic 2 (1.7)
Head and neck (other) 2 (1.7)
Cholangiocarcinoma 1 (0.8)
Adenocarcinoma of upper GI tract 1 (0.8)
Neuroblastoma 1 (0.8)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; GI, gastrointestinal; MASC, mammary analog secretory carcinoma.

aLines of therapy determined from the time of metastatic disease diagnosis.

bPrevious therapy in any setting.

cCNS metastases status as per investigator assessment.

dAmong patients with baseline CNS metastases per investigator assessment.

eAmong patients with baseline CNS metastases and prior radiotherapy of the brain.

fPatients may have had multiple sites of metastases at baseline.